Advertisement

Topics

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

2010-07-15 17:00:00 | BioPortfolio

Summary

The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Conditions

Pheochromocytoma

Location

Oxford Outcomes- Nationwide Recruitment within the US
Bethesda
Maryland
United States
20814

Status

Recruiting

Source

Molecular Insight Pharmaceuticals, Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.

Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma

Pheochromocytoma or paraganglioma are tumors generating hypertension as a symptom. Different biological tests are currently available to diagnose these tumors. However, they all lack speci...

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

- According to Martin F et al, AKT is highly phosphorylated in phenochromocytoma but not in benign adrenocortical tumors. - In nonfunctioning carcinoid, the PI3K/AKT/mTOR pathway...

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for pati...

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 mont...

PubMed Articles [49 Associated PubMed Articles listed on BioPortfolio]

microRNA 183 family profiles in pheochromocytomas are related to clinical parameters and SDHB expression.

This study aims to examine the expression profiles of the miR-183 cluster (miR-96/182/183) in pheochromocytoma. Pheochromocytoma tissues were prospectively collected from 50 patients with pheochromocy...

Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy.

Catecholamine excess from pheochromocytoma results in cardiovascular symptoms such as arterial hypertension and tachycardia and induces metabolic alterations including glucose intolerance and increase...

Pheochromocytoma, diagnosis and treatment: Review of the literature.

We conducted an extensive review of the literature and tried to cite the most recent recommendations concerning the pheochromocytoma (PHEO).

Malignant Pheochromocytoma and Paraganglioma: 272 Patients over 55 Years.

Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited.

Pheochromocytoma-Induced Cardiomyopathy Mimicking Acute Coronary Syndrome.

Pheochromocytoma is a rare catecholamine-secreting tumor with a prevalence of 0.1% to 0.6% in hypertensive patients. The classic triad of symptoms is headache, palpitations, and diaphoresis, but clini...

Medical and Biotech [MESH] Definitions

A selective adrenergic alpha-1 antagonist used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention.

A benzodioxane alpha-adrenergic blocking agent with considerable stimulatory action. It has been used to diagnose PHEOCHROMOCYTOMA and as an antihypertensive agent.

An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)

A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.

A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)

More From BioPortfolio on "Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma"

Quick Search
Advertisement
 

Searches Linking to this Trial